There are currently 824 clinical trials in Phoenix, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Phoenix Children's Hospital, GSK Investigational Site, Mayo Clinic Arizona and Mayo Clinic. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410
Recruiting
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemip... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Medical Dermatology Specialists, Phoenix, Arizona
Conditions: Cutaneous Squamous Cell Carcinoma (CSCC)
Register for Updates
Pediatric Down Syndrome Post-Approval Study
NCT06851338
Recruiting
The purpose of this Post Approval research study is to assess ongoing safety and effectiveness of the Inspire therapy in adolescents and young adults (age 13-18) with Down syndrome and severe sleep apnea. The objective of the study is to provide an ongoing safety and effectiveness assessment of the Inspire UAS System in the Pediatric Down syndrome population.
Gender:
ALL
Ages:
Between 13 years and 18 years
Trial Updated:
02/24/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Pediatric Obstructive Sleep Apnea, Down Syndrome (DS)
Register for Updates
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
NCT05556824
Recruiting
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/21/2025
Locations: Elite Clinical Studies LLC, Phoenix, Arizona
Conditions: Gastroesophageal Reflux
Register for Updates
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
NCT06337708
Recruiting
The purpose of this study is to test a culturally tailored, smartphone-delivered intervention designed to increase physical activity and reduce risk for heart disease and type 2 diabetes among African American women.
Gender:
FEMALE
Ages:
Between 24 years and 65 years
Trial Updated:
02/21/2025
Locations: Arizona State University, Phoenix, Arizona
Conditions: Physical Activity, Exercise, Heart Diseases, Diabetes Mellitus, Physical Inactivity
Register for Updates
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688
Recruiting
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/21/2025
Locations: Barrow Neurological Institute, Phoenix, Arizona
Conditions: Alzheimer Disease
Register for Updates
Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
NCT06153420
Recruiting
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo. * To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo Participants will attend the foll... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Elite Clinical Studies LLC, Phoenix, Arizona
Conditions: Irritable Bowel Syndrome With Diarrhea
Register for Updates
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302
Recruiting
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona
Conditions: Lymphoma, Follicular
Register for Updates
Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
NCT06581159
Recruiting
A Study of HS135 for the Treatment of in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Site-104, Phoenix, Arizona
Conditions: Heart Failure with Preserved Ejection Fraction, Pulmonary Hypertension
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
NCT06627647
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Research Site, Phoenix, Arizona
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Phoenix, Arizona
Conditions: Generalized Anxiety Disorder
Register for Updates
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End Stage Renal Disease
NCT04671771
Recruiting
The goal of the CSP-2002 clinical trial is to evaluate the safety and effectiveness of the InnAVasc Arteriovenous Graft (IG) for hemodialysis (HD) access in patients with end-stage renal disease (ESRD). The primary study endpoints are: Primary Effectiveness Endpoint: The proportion of subjects with secondary patency at 6 months. Primary Safety Endpoint: The incidence of device-related adverse events of special interest (AESIs) through 6 months. Participants will be asked to sign an informed c... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/19/2025
Locations: AKDHC Medical Research Services, LLC, Phoenix, Arizona
Conditions: End Stage Renal Disease (ESRD), Kidney Failure, Chronic Renal Disease, Hemodialysis
Register for Updates
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376
Recruiting
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Research Site, Phoenix, Arizona
Conditions: Immunoglobulin A Nephropathy, IgAN
Register for Updates